{"id":"W4399993529","doi":"10.1016/s1470-2045(24)00211-0","title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"National Cancer Institute; EMD Serono; Ipsen; Eisai; National Institutes of Health; ECOG-ACRIN Cancer Research Group; Canadian Cancer Society; Sanofi; Exelixis; Dana-Farber/Harvard Cancer Center; Genentech; Coherus Biosciences; Bristol-Myers Squibb; Pfizer; Dana-Farber Cancer Institute; American College of Radiology Imaging Network; Veracyte","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Clinical endpoint; Perioperative; Kidney cancer; Internal medicine; Surgery; Clinical trial; Urology; Cancer; Kidney; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006563278,0.0003082501,0.0008252027,0.0001162848,0.0001539173,0.0001256288,0.0003288249,0.00009917901,0.0001524459],"category_scores_gemma":[0.00004873685,0.0001881548,0.00003493424,0.0003845719,0.0001037257,0.0003265077,0.000151091,0.0004529538,0.00004918465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001057494,"about_ca_system_score_gemma":0.000669726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004585417,"about_ca_topic_score_gemma":0.002025521,"domain_scores_codex":[0.9976153,0.0006190166,0.0004035295,0.0006000752,0.0003069485,0.0004550847],"domain_scores_gemma":[0.9986873,0.0003837957,0.0001053753,0.0005742001,0.0001256909,0.0001236739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4494388,0.01968241,0.4810589,0.0002895119,0.0007564183,0.002500726,0.02128219,0.0001627939,0.005065277,0.0002876704,0.00125175,0.01822358],"study_design_scores_gemma":[0.5979553,0.06754765,0.3265992,0.0001093057,0.0005862667,0.00002653305,0.001867227,0.001297451,0.001115454,0.00001950986,0.002529403,0.0003467865],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890164,0.0003176966,0.00001719969,0.0007790131,0.0003563117,0.004416717,0.00001589462,0.00006826124,0.005012468],"genre_scores_gemma":[0.9969372,0.00001910258,0.001034836,0.0003114301,0.0002988116,0.0005570424,0.0001366127,0.00005505478,0.0006498949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1544597,"threshold_uncertainty_score":0.7672728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09033592788829715,"score_gpt":0.3633928836903327,"score_spread":0.2730569558020355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}